https://doi.org/10.31288/oftalmolzh201415260

Immunocorrection effect of the drug Amixin in patients with uveal melanoma during combined organ-preserving treatment

Velichko L. N.

The Filatov Institute of Eye Diseases and Tissue Therapy of Ukrainian National medical academy, Odessa, Ukraine

Key words: uveal melanoma, complex treatment, molecular markers of lymphocyte activation, amixin

Introduction. Unsatisfactory results of traditional methods of treatment of patients with uveal melanoma conditioned the search for a new complex approach to the organ-preserving therapy. Lately it has been shown that realization of the organ-preserving treatment depends on the activation of the immunologic systems of the patient's organism.

Purpose of the investigation. To study the possibility of using Amixin in the complex treatment of patients with uveal melanoma.

Materials and methods. The investigation was carried out in 83patients with uveal melanoma. The patients were divided into two groups: I group — 43 patients with uveal melanoma who were made photocoagulation and ?-therapy against the background of interferon inductor — amixin; II group — 40 patients without using immunologic correction. There was also made the study of the level of expression of the molecular markers of lymphocyte activation CD7+ CD38+ CD45+, CD54+, CD95+, CD150+ by the histoimmunochemical method before the beginning of treatment, in 3 and 9 months after treatment.

Results. The patients with uveal melanoma whose combined therapy was given against the background of amixin had the tumour prominence reliably higher than patients that did not take amixin and made 7.4 (SD 3.1) mm versus 5.8 (SD 2.9) mm, p+0.001

The tumour volume was also higher in patients that took amixin and made 66.8 (SD 32.7) mm3 and in patients who did not take amixin it was 52.8 (SD 31.2) mm3, p+0.05.

Despite the fact that the tumour size in the group of patients taking amixin was higher, failures of the organ-reserving treatment was 7.4 % versus 23.8 % in the group of patients who did not have immunocorrection therapy. There was noted reliable increase of the level of CD95+ and CD7+ expression in 3 months after intake of amixin. In 9 months the patients who took amixin were ob-served to have reliable increase inn comparison with the initial level of expression of CD95+ CD25+ CD38+, CD54+ (only absolute indices), CD150+, CD45+, CD7+ In 3 months the level of molecular markers of lymphocyte activation did not increase reliably in patients with uveal melanoma whose combined therapy did not include amixin. In 9 months in comparison with the initial level there was noted reliable increase of the expression of relative content of CD95+, absolute content of CD150+, absolute and relative content of CD45+ and CD7+. 

Conclusion. It is established that inclusion of amixin in the complex therapy of patients with uveal melanoma allows to destruct tumours of the large size as well as contribute to reduction in the enucleation rate. The positive effect of using amixin in patients with uveal melanoma is associated with authentic increase of the expression level of CD54+ and CD95+ molecules promoting a positive result of the organ-preserving treatment.

References

1.Alenov MN. The influence of amixin on interferon status in patients with chronic hepatitis C. VII Russian Congress «Man and Medisine». M.; 2000. 389.

2.Amixin — possibility and perspectives for application in clinic practice (Informational and analytic digest). Odessa; 2001. 36 p.

3.Androinati SA, Litvinova LA, Golovenko NYa. Oral endogenous interferon inducer «Amixin» and its analogues. Zhurnal AMN Ukrainy. 1999;5(1):53- 66. Russian.

4.Bogatskii AV, Zaporozhan VN, Andronati SA. The influence of Tilorone on some immunological parameters in guinea pigs with glandular endometrial hyperplasia induced by Synoestrol. Eksperimentalnaia onkologiia. 1985;1:61-4. Russian.

5.Velichko LM, Vit VV, Dragomiretska OI. ?2?-interferon immunocorrection — an important component of treatment for patients with uveal melanoma. Onkologiia. 2000;2(2):64-7. Ukrainian.

6.Velichko LM. a2p-interferon immunocorrection — an optimizing component in treatment of uveal melanoma patients: Author's thesis for Candidate of Medical Sciences: spec. 14.01.07 «Oncology». Kiev; 2000. 19 p.

7.Velichko LN. Immunological effects of interferon. Oftal-mol Zh. 1997;6:449- 52. Russian.

8.Velichko LN, Maletskii AP, Vit VV, Bogdanova AV. Prediction of organ-effectiveness of organ-preserving treatment for uveal melanoma patients using molecular markers of lymphocyte activation. Zagalna patologiia і patologichna fisiologiia. 2013;4:14-8. Russian.

9.Velichko LN. The level of expression of lymphocytes activation molecular markers in peripheral blood in uveal melanoma patients with varying efficacy of organ-preserving treatment. Oftalmol Zh. 2013; 5:9-13. Russian.
Crossref

10.Velichko LN, Maletskii AP. Cytocinematherapy of uveal melanoma patients. Immunological aspects. Laferon in treatment of oncologic and inflammatory diseases. Rivne: Volynski litavry; 1996. 47- 48.

11.Vit VV. Tumor pathology of the eye. Vol.1. Odessa: Astroprint; 2009. 610 p.

12.Vit VV. Pathological anatomy and medical pathomorphosis of pigmented uveal tract neoplasms of the human eye: Author's thesis for Doctor of Medical Sciences. Odessa; 1987. 30 p.

13.Vorontsova AL, Kudryavets YuI. Interferon as an important optimizing component for oncologic patient treatment. Onkologiia. 2000;2(1-2):16-20. Russian.

14.Vorontsova AL. The role of interferon in antitumor resistance. Eksperimentalnaia onkologiia. 1989;11(6):49- 54. Russian.

15.Gluzman SS, Sklyarenko LM, Nadgornaya VA, Kryachok IA. Diagnostic immunocytochemistry of the tumor. Kiev:Morion; 2003. 6- 15.

16.Grigoryan SS, Ivanova AM, Khodzhayev ShKh, Yershov FI. Interferon activity of amixin and its effect on interferon status. Voprosy virusologii. 1990;35(1):61-4. Russian.

17.Yershov FI. Amoxin — a corrector of the system of immu-nity and interferon. V Russian Congress «Man and Medicine». M.; 1998: 503.

18.Kudryavets YuI. Interferon-alpha enhances the development of apoptosis induced by various agents in tumor cells in vitro. Experimental Oncology. — 2003;23:267-3.

19.Malashenkova IK. Influence of single intake of amexin on the interferen status. V Russian Congress «Man and Medicine». M.; 1998: 503.

20.Borden EC, Edwards BS, Hawkins MJ, Merritt JA. Interferons: biological response modification and pharmacology. Biological Responses in Cancer. 1982; 169218.
Crossref

21.Castelli JC, Hassel BA, Wood KA et al. A study of the in-terferon fntiviral mechanism: apoptosis activation by the 2-5A system. J. Exp. Med. 1997;1869(6):967- 72.
Crossref

22.Dao T, Ariyasu T, Holan V, Minowada J. Natural human interferon-alpha augments apoptosis in activated T-cell line. Cell Immunol. 1994;155:304- 11.
Crossref

23.Hitoshi H, Imai M, Yamanaka M. The interferon-a2b gene in Japanese patients with chronic viral hepatitis who developed antibodies after treatment with recombinant interferon-a2a. J. Gastroenterology Hepatology. 1992;7:411-6.
Crossref

24.Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastasis: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1995;1:149- 53.
Crossref

25.Rabinovitch M, Manejias RE. Anti-interferon globulin inhibits macrophage phagocytic enhancement in vivo by tilorone or Newcastle disease virus. Cell. Immunol. 1978;39(2):402-6.
Crossref

26.Schellekens H. Antibodies as antagonist to treatment recombinant DNA-derived cytokines — measurement and biological significance. Special Supplement Report from the 1996 Annual Meeting of the ISICR.

27.Vallbracht A, Treuner T, Flehmig B et al. Interferon neutralizing antibodies in a patient treated with human fibroblast interferon. Nature. 1981;287:496-8.
Crossref   Pubmed